AXIM Biotechnologies Engages 624 Advisors, Owned and Managed by Dr. Alan J. Touch, Innovator and Global Regulatory Leader, as Chief Medical & Regulatory Affairs Advisor
MWN-AI** Summary
AXIM Biotechnologies, Inc. (OTC: AXIM), a diagnostic and biotechnology firm focused on ocular and inflammatory diseases, has announced the engagement of 624 Advisors, managed by Dr. Alan J. Touch, as its Chief Medical & Regulatory Affairs Advisor. Dr. Touch is a highly regarded expert in in vitro diagnostics (IVD) and companion diagnostics (CDx), bringing over three decades of leadership experience in diagnostics, medical devices, pharmaceuticals, and digital health.
Dr. Touch played a pivotal role in the development of ocular diagnostic technologies that AXIM now utilizes, and he is also known for inventing the world’s first colored contact lens. His extensive background includes senior roles at Bausch & Lomb and INC Research, as well as founding 624 Advisors, which specializes in product development, regulatory strategy, and quality compliance.
AXIM’s CEO, Catalina Valencia, emphasized the importance of this strategic engagement, highlighting Dr. Touch's unique blend of inventor-level knowledge and significant regulatory experience. His involvement is expected to enhance AXIM’s regulatory strategies, quality assurance, and clinical execution, vital as the company approaches key milestones, including FDA 510(k) submissions and international expansion.
Dr. Touch’s expertise aligns closely with AXIM's goals, offering deep insight into immunoassay diagnostics, FDA regulations, and global frameworks. His leadership aims to reduce reliance on external consultants and accelerate readiness for commercialization.
In addressing his new role, Dr. Touch expressed enthusiasm for joining AXIM at this crucial juncture, looking forward to supporting the company's efforts in regulatory excellence and product development. AXIM develops point-of-care diagnostic tests, notably its TearScan® platform, which enhances diagnostic accuracy for clinicians via tear biomarker analysis. For further details, visit www.aximbiotech.com.
MWN-AI** Analysis
AXIM Biotechnologies, Inc. (OTC:AXIM) has strategically positioned itself for significant growth by engaging Dr. Alan J. Touch of 624 Advisors as Chief Medical & Regulatory Affairs Advisor. This decision marks a pivotal step in AXIM's journey toward regulatory milestones and commercial success, especially as the company advances its TearScan® platform for ocular and systemic health. Dr. Touch's impressive background, spanning over three decades in the diagnostic and healthcare sectors, provides AXIM with a wealth of knowledge and experience.
Investors should view this engagement not only as a mere addition to the team but as a strong signal regarding AXIM’s commitment to navigating the complex regulatory landscape. Dr. Touch’s deep expertise in FDA regulations and his inventor-level understanding of diagnostics, particularly in relation to lactoferrin and immunoassay technology, enhances AXIM's credibility. His track record of successfully leading product development and regulatory affairs positions the company for accelerated readiness for commercialization.
Furthermore, as the company prepares for critical FDA 510(k) submissions and international expansions, Dr. Touch’s support in strengthening quality systems and operational scale is crucial. This could lead to improved market confidence in AXIM's products, potentially driving stock performance.
Considering AXIM’s ambitious roadmap and the current healthcare market's focus on rapid, point-of-care diagnostics, the strategic hire of Dr. Touch presents an opportunity for robust growth. Potential investors might want to keep an eye on upcoming regulatory hurdles and product launches as these will likely impact stock valuations. Overall, AXIM Biotechnologies appears to be well-positioned for growth with a focus on regulatory excellence and market-driven innovations.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
SAN DIEGO, CA - January 20, 2026 (NEWMEDIAWIRE) - AXIM Biotechnologies, Inc. (“AXIM” or the “Company”) (OTC:AXIM), a diagnostic and biotechnology company advancing clinically validated solutions for ocular and inflammatory diseases, today announced the engagement of 624 Advisors, which is owned and managed by Alan J. Touch, OD, as Chief Medical & Regulatory Affairs Advisor. Dr. Touch is considered a preeminent IVD and CDx SME and global regulatory specialist.
Dr. Touch brings more than three decades of global leadership across diagnostics, medical devices, pharmaceuticals, and digital health. He is the original co-inventor of the first ocular diagnostic technologies acquired by AXIM, the inventor of the world’s first colored contact lens, formerly headed up Clinical Affairs at Bausch & Lomb and was Principal Strategist for Ophthalmology, Medical Devices and Diagnostics at INC Research (Syneos Health). As Chief Science Officer of an ophthalmic CDMO, he led the development of several proprietary dry eye disease (DED) products including the first eye drop based on addressing the Inflammatory Cascade through a novel pathway. He has been a successful health care entrepreneur as well as providing senior leadership roles for major international healthcare organizations. He founded 624 Advisors as a product development, regulatory and quality compliance consultancy. The engagement of 624 Advisors, led by Dr. Touch, provides AXIM with enhanced technical continuity, regulatory depth, and strategic execution capability at a pivotal stage of the Company’s development.
“This strategic engagement is an important addition to the R&D and regulatory team at AXIM,” said Catalina Valencia, President and CEO of AXIM Biotechnologies. “Dr. Touch uniquely combines inventor-level knowledge of our technology with significant senior level experience in FDA regulation, ISO quality systems, clinical development, and manufacturing readiness. His involvement strengthens our regulatory strategy, quality foundation, and clinical execution, while positioning AXIM for efficient global expansion and long-term operational scale. As AXIM advances toward key regulatory and commercial milestones, including upcoming FDA 510(k) submissions, international regulatory expansion, and the establishment of a robust quality and manufacturing infrastructure, Dr. Touch’s advisory role is designed to provide highly qualified support across these areas. AXIM is very pleased to welcome Dr. Touch to our team.”
Dr. Touch's background uniquely aligns with AXIM's current efforts and upcoming goals and milestones:
- Inventor-level understanding of lactoferrin and immunoassay diagnostics
- Deep experience across FDA, EU MDR/IVDR, and global regulatory frameworks
- Proven leadership in regulatory affairs, quality systems, clinical development, and manufacturing scale-up
- Reduced reliance on external consultants
- Accelerated readiness for commercialization and global growth
- Knowledge of the methodology to build a milestone-based product development Vale Proposition
“I am pleased to work with AXIM at this important stage and to continue advancing technology I originally helped develop,” said Dr. Alan J. Touch. “AXIM is building a strong foundation for market-sensitive and aware regulatory excellence and clinical credibility for its products. I look forward to supporting an excellent and cohesive scientific, marketing and operational team as they advance key submissions, strengthen quality systems, and prepare for long-term manufacturing and commercial success.”
About AXIM Biotechnologies, Inc.
AXIM Biotechnologies, Inc. develops and commercializes rapid , point-of-care diagnostic tests focused on ocular and systemic health. Its TearScan® platform enables clinicians to quantify tear biomarkers with laboratory-grade accuracy in office settings, enhancing diagnostic confidence and treatment outcomes. For more information, visit www.aximbiotech.com.
Corporate/Media Contact
+1 858-256-5132
hello@aximbiotech.com
Forward-Looking Statements
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the statements made herein.
View the original release on www.newmediawire.com
FAQ**
How does Axim Biotechnologies Inc AXIM plan to leverage Dr. Alan J. Touch's expertise in regulatory affairs to enhance its market entry strategies for upcoming FDA 510(k) submissions?
In what ways does Axim Biotechnologies Inc AXIM expect Dr. Touch’s co-inventor status of ocular diagnostic technologies to impact its R&D and product development processes moving forward?
What specific milestones are set by Axim Biotechnologies Inc AXIM that Dr. Touch's engagement aims to accelerate in terms of regulatory compliance and global market expansion?
How does Axim Biotechnologies Inc AXIM intend to refine its quality and manufacturing infrastructure under Dr. Touch's guidance to ensure readiness for commercialization?
**MWN-AI FAQ is based on asking OpenAI questions about Axim Biotechnologies Inc (OTC: AXIM).
NASDAQ: AXIM
AXIM Trading
19.77% G/L:
$0.0103 Last:
83,500 Volume:
$0.0109 Open:
